Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.52
(
2.91%
)
US TECH 100
23,161.07
(
3.72%
)
Dow Jones
46,341.51
(
2.49%
)
Brent Oil
104.36
(
1.18%
)
Bitcoin
68,192.68
(
-0.11%
)
News Focus
News Focus
Post# of 257323
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 36
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: biomaven0 post# 127347

Monday, 09/26/2011 11:36:02 AM

Monday, September 26, 2011 11:36:02 AM

Post# of 257323
Peter,

Assuming that Ponatinib gets approved for third-line therapy, would reimbursement issues prevent doctors from using Ponatinib in first-line or second-line, if they chose to do so?


Bladerunner


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today